Internal Medicine – Page 6

Beta-Cell Function, Not Glucagon, Predicts Glycemic Success: A Critical Analysis of the GRADE Study

By MedXY 01/23/2026

A sub-analysis of the GRADE study reveals that beta-cell function (C-peptide index), rather than alpha-cell responses (glucagon), is the primary driver of glycemic durability in type 2 diabetes across various medication classes, suggesting therapeutic focus should remain on beta-cell preservation.

Diabetes & Endocrinology Internal Medicine news

Challenging the Metformin Monopoly: Insights from the SMARTEST Trial on Early-Stage Type 2 Diabetes Management

By MedXY 01/22/2026

The SMARTEST trial investigates whether dapagliflozin should replace metformin as first-line therapy for early type 2 diabetes. Baseline data reveals a surprisingly high microvascular event rate, highlighting the urgent need for early organ protection in newly diagnosed patients.

Internal Medicine news Respiratory

Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation

By MedXY 01/22/2026

A multicentre feasibility trial demonstrates that Singing for Lung Health (SLH) is a viable follow-up to pulmonary rehabilitation, showing high retention rates and strong participant enthusiasm for a definitive randomized controlled trial.

Cardiology Internal Medicine news

Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden

By MedXY 01/21/2026

A post hoc analysis of the CABANA trial reveals that catheter ablation significantly reduces major cardiovascular events and improves quality of life in AF patients with high comorbidity burden (≥4 conditions), suggesting that multimorbidity should not be a barrier to invasive rhythm control strategies.

Gastroenterology Internal Medicine news

Mediterranean Diet Outperforms Traditional Dietary Advice for Irritable Bowel Syndrome: A Landmark Randomized Trial

By MedXY 01/20/2026

A randomized clinical trial published in the Annals of Internal Medicine reveals that the Mediterranean diet is superior to traditional dietary advice for managing IBS symptoms, offering a nutrient-dense, sustainable first-line intervention with a 62% clinical response rate.

Gastroenterology Internal Medicine news

Is 2 Liters of PEG Necessary? Simplified Water Prep Proves Effective for Crohn’s Capsule Endoscopy

By MedXY 01/20/2026

A randomized trial demonstrates that a simplified bowel preparation using clear liquids and water offers comparable diagnostic yield and cleanliness to PEG-based regimens for Crohn’s disease capsule endoscopy, while significantly improving patient acceptability and comfort.

Hematology-Oncology Internal Medicine news

Iptacopan Demonstrates Clinical Efficacy in Cold Agglutinin Disease While Falling Short in Immune Thrombocytopenia: Results from a Phase 2 Basket Trial

By MedXY 01/19/2026

This Phase 2 basket trial highlights the divergent efficacy of the oral factor B inhibitor iptacopan, showing significant hemoglobin improvements in Cold Agglutinin Disease but failing to meet platelet response endpoints in Immune Thrombocytopenia.

Cardiology Internal Medicine news Pathology & Lab Medicine

NT-proBNP-Defined Heart Stress: A New Compass for Individualized Blood Pressure Targets in Older Adults?

By MedXY 01/18/2026

A post hoc analysis of the ASPREE trial reveals that heart stress, measured by NT-proBNP, significantly alters the relationship between blood pressure and cardiovascular risk in older adults, suggesting a paradigm shift toward biomarker-guided hypertension management.

Cardiology Internal Medicine news

Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER

By MedXY 01/18/2026

A critical reanalysis of the DAPA-HF and DELIVER trials reveals that the survival proportional odds model provides greater statistical power and more robust treatment effect estimates than traditional Cox regression in heart failure populations characterized by high risk heterogeneity.

Cardiology Internal Medicine news

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

By MedXY 01/18/2026

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting the complexities of implementing precision medicine in clinical practice.

Cardiology Internal Medicine news

Aspirin vs. Clopidogrel Beyond 30 Days Post-PCI: Equivalent Outcomes Regardless of Oral Anticoagulation Status

By MedXY 01/18/2026

A subgroup analysis of the STOPDAPT-3 trial reveals that aspirin and clopidogrel offer similar cardiovascular protection and bleeding safety between 1 month and 1 year post-PCI, regardless of whether patients are also receiving oral anticoagulation.

Cardiology Internal Medicine news

Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF

By MedXY 01/17/2026

The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention where baseline performance is already high.

Cardiology Internal Medicine news

Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial

By MedXY 01/17/2026

The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiology Internal Medicine news

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial

By MedXY 01/17/2026

The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering ischemic risks without increasing bleeding.

Cardiology Internal Medicine news

Finerenone Provides Robust Protection Against Heart Failure Events Regardless of Baseline NYHA Functional Class

By MedXY 01/16/2026

A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those with more severe functional limitations.

Cardiology Internal Medicine news

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

By MedXY 01/16/2026

The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microvascular health and maintaining patient quality of life.

Gastroenterology Internal Medicine news

Ethosuximide Fails to Relieve IBS-Related Abdominal Pain: Results from a Multicenter Randomized Controlled Trial

By MedXY 01/16/2026

A multicenter RCT found that ethosuximide, a T-type calcium channel blocker, did not improve abdominal pain in IBS patients compared to placebo and was associated with significant tolerability issues, highlighting the need for more selective pharmacological targets.

Infectious Diseases Internal Medicine news

Beyond the Hospital Walls: Can Prospective Audit and Feedback Solve the Discharge Antibiotic Dilemma?

By MedXY 01/16/2026

A multicenter stepped-wedge trial reveals that while prospective audit and feedback by stewardship teams improves the quality of discharge antibiotic prescribing, it fails to reduce the overall volume or duration of therapy, highlighting the complexity of the discharge transition.

Cardiology Internal Medicine news

Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?

By MedXY 01/16/2026

This randomized clinical trial investigates whether returning opportunistic genomic results for familial hypercholesterolemia to veterans impacts LDL-C levels. While the primary endpoint missed statistical significance, the findings suggest a potential clinical benefit in treatment intensification and family communication.

Internal Medicine news Respiratory

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial

By MedXY 01/13/2026

The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.